Isatuximab Added to RVd Boosts Response in New Myeloma Isatuximab Added to RVd Boosts Response in New Myeloma
The addition of the anti-CD38 antibody improved minimal residual disease rates at the end of induction, a marker for better outcomes following autologous stem cell transplant.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Health | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Transplants